scholarly journals Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018

2021 ◽  
Author(s):  
Rose J. Geurten ◽  
Jeroen N. Struijs ◽  
Arianne M. J. Elissen ◽  
Henk J. G. Bilo ◽  
Chantal van Tilburg ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
The Netherlands ◽  
Specialist Care ◽  
Claims Database ◽  
Medication Utilization

scholarly journals Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e049487
Author(s):  
Rose J Geurten ◽  
Arianne M J Elissen ◽  
Henk J G Bilo ◽  
Jeroen N Struijs ◽  
Chantal van Tilburg ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
The Netherlands ◽  
Health System ◽  
Pharmaceutical Care ◽  
Healthcare Utilisation ◽  
Medical Specialist ◽  
Specialist Care ◽  
Policy And Practice ◽  
Claims Database

ObjectivesWe aimed to identify and delineate the Dutch type 2 diabetes population and the distribution of healthcare utilisation and expenditures across the health system from 2016 to 2018 using an all-payer claims database.DesignRetrospective observational cohort study based on an all-payer claims database of the Dutch population.SettingThe Netherlands.ParticipantsThe whole Dutch type 2 diabetes population (n=900 522 in 2018), determined based on bundled payment codes for integrated diabetes care and medication use indicating type 2 diabetes.Outcome measuresAnnual prevalence of type 2 diabetes, comorbidities and characteristics of the type 2 diabetes population, as well as the distribution of healthcare utilisation and expenditures were analysed descriptively.ResultsIn 2018, 900 522 people (6.5% of adults) were identified as having type 2 diabetes. The most common comorbidity in the population was heart disease (12.1%). Additionally, 16.2% and 5.6% of patients received specialised care for microvascular and macrovascular diabetes-related complications, respectively. Most patients with type 2 diabetes received pharmaceutical care (99.1%), medical specialist care (97.0%) and general practitioner consultations (90.5%). In total, €8173 million, 9.4% of total healthcare expenditures, was reimbursed for the type 2 diabetes population. Medical specialist care accounted for the largest share of spending (38.1%), followed by district nursing (12.4%), and pharmaceutical care (11.5%).ConclusionsAll-payer claims databases can be used to delineate healthcare use: this insight can inform health policy and practice and, thereby, support better decisions to promote long-term sustainability of healthcare systems. The healthcare utilisation of the Dutch type 2 diabetes population is distributed across the health system and utilisation of medical specialist care is high. This is likely to be due to presence of concurrent morbidities and complications. Therefore, a shift from a disease-specific approach to a person-centred and integrated care approach could be beneficial in the treatment of type 2 diabetes.

scholarly journals Current Status Of Comorbid Depression Among Japanese Type 2 Diabetes Patients Based On Claims Database Analysis

2016 ◽  
Vol 19 (3) ◽  
pp. A182
Author(s):  
T Takeshima ◽  
K Iwasaki ◽  
A Uda ◽  
S Hiroi ◽  
Y Shimasaki
Keyword(s):  
Type 2 Diabetes ◽  
Current Status ◽  
Comorbid Depression ◽  
Database Analysis ◽  
Claims Database ◽  
Diabetes Patients

Obesity and Serum High Sensitivity C-Reactive Protein Levels Among Elderly Turkish Immigrants in the Netherlands with Type 2 Diabetes

2012 ◽  
Vol 39 (1) ◽  
pp. 68-80 ◽  
Author(s):  
Shiryn D. Sukhram ◽  
Gustavo G. Zarini ◽  
Lamya H. Shaban ◽  
Joan A. Vaccaro ◽  
Fatma G. Huffman
Keyword(s):  
Type 2 Diabetes ◽  
The Netherlands ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Turkish Immigrants ◽  
Protein Levels ◽  
Reactive Protein

OP91 Estimating prevalence and incidence of type 1 and type 2 diabetes in Ireland using the national pharmacy claims database

2015 ◽  
Vol 69 (Suppl 1) ◽  
pp. A49.2-A49
Author(s):  
SJ Sinnott ◽  
S McHugh ◽  
R Layte ◽  
H Whelton ◽  
PM Kearney
Keyword(s):  
Type 2 Diabetes ◽  
Claims Database ◽  
Pharmacy Claims

scholarly journals PDB81 - DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

2018 ◽  
Vol 21 ◽  
pp. S132
Author(s):  
S.P. Van Olst ◽  
S. Nekeman ◽  
N. van der Linden ◽  
C.A. Uyl-de Groot
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
The Netherlands ◽  
Cost Effective
Sign in / Sign up

Export Citation Format

Share Document